Development of novel targeted therapy using retrograde superselective IA-CCRT on oral cancer

• Project/Area Number: 25861965
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Surgical dentistry
• Research Institution: Yokohama City University
• Principal Investigator: MITSUNAGA Sachiyo 横浜市立大学, 医学(系)研究科(研究院), 客員研究員 (20567606)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 分子標的薬 / 分子標的治療

Outline of Final Research Achievements

The problem of current cancer therapy for the treatment of patients with advanced oral cancer contains functional disorders such as dysphasia, mastication disorder, cosmetic problem after the surgery. To avoid this, we have proposed the novel therapeutic strategy using retrograde superselective intra-arterial chemoradiotherapy with targeted agents. We found the significant phosphorylation of EGFR in oral cancer cell lines. In mice, subcutaneous oral tumor was most effectively treated with intraperitoneally injected cetuximab and intratumoral injection of docetaxel.